Practical Management Strategies and New Innovations in Prostate Radiotherapy

Thursday-Friday December 8-9, 2016

Conference Location:
Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street New York, NY 10065

Featuring World Renowned Speakers Covering Cutting-Edge Topics

CALL FOR ABSTRACTS
Course Overview

The course will include coverage of the following topics:

- Comparing outcomes for surgery and radiotherapy in clinically localized prostate cancer
- Optimal management strategies to treat acute and late side effects of radiotherapy
- Tips for reducing errors and improving QA for prostate Brachytherapy
- Updates on SBRT and Proton therapy in the treatment of prostate cancer
- Salvage radiotherapy after primary treatment failures and expected toxicity outcomes
- Optimal integration of hormonal therapy with prostate radiotherapy
- New developments in External Beam Treatment Planning including MR-Treatment Planning
- Guidelines for the Radiation Oncologist contouring target and nodal regions
- Integrating imaging into treatment selection and treatment planning

TARGET AUDIENCE

The target audience includes Radiation Oncologists, Urologists, Medical Oncologists, Medical Physicists, Radiation Therapists, Nurses and Residents.

CALL FOR ABSTRACTS

Participants are invited to submit an abstract for presentation at the meeting. Abstracts for the poster session will be selected on the basis of their scientific merit and content quality. Visit the conference website for more information: www.mskcc.org/radiotherapy.
MSK FACULTY

Stefan Both PhD
Associate Attending Physicist
Department of Medical Physics

Oren Cahlon MD
Asst Attending Radiation Oncologist
Department of Radiation Oncology

Gilad Cohen MS
Senior Radiotherapy Physicist
Department of Medical Physics

Jonathan Coleman MD
Associate Attending Surgeon
Urology Service
Department of Surgery

James Eastham MD
Chief, Urology Service
Department of Surgery

Richard M. Gewanter MD
Asst Attending Radiation Oncologist
Commack/Rockville Center
Dept of Radiation Oncology

Laura Happersett MS
Senior Radiotherapy Physicist
Department of Medical Physics

Margie A. Hunt MS
Chief of Clinical Physics Service
Department of Medical Physics

Philip Kantoff MD
Chairman of Medicine
Department of Medical Oncology

James G. Mechalakos PhD
Section Head of External Beam Treatment
Department of Medical Physics

John P. Mulhall MD
Attending Surgeon
Urology Service
Department of Surgery

Evis Sala MD PhD
Chief Attending
Department of Radiology

Jaspreet S. Sandhu MD
Associate Attending Surgeon
Urology Service
Department of Surgery

Heiko Schoder MD
Deputy Chief of Molecular Imaging
and Therapy Service
Department of Radiology

Susan F. Slovin MD PhD
Attending Medical Oncologist
Department of Medical Oncology

Neelam Tyagi PhD
Assistant Attending Physicist
Department of Medical Physics

INVITED FACULTY

Kristy Brock-Leatherman PhD
Assoc Professor of Nuclear Engineering & Radiological Sciences
Assoc. Professor of Radiation Oncology
University of Michigan
Ann Arbor, MI

Juanita Crook MD
Professor of Radiation Oncology
University of British Columbia
Vancouver, BC, Canada

Anthony Victor D’Amico MD PhD
Professor of Radiation Oncology,
Harvard Medical School
Chief of Genitourinary Radiation Oncology,
Brigham and Women’s Hospital
Boston, MA

Mark Emberton MD
Dean, Faculty of Medical Sciences
University College London
London, United Kingdom

Steven Jay Frank MD
Assoc Professor of Radiation Oncology
Deputy Department Chair, Strategic Programs
Proton Center Medical Director
MD Anderson Cancer Center
Houston, TX

Carri Glide-Hurst PhD
Senior Staff Physicist
Henry Ford Hospital
Detroit, MI

Carlo Greco MD
Director of Clinical Research
Champalimaud Centre for the Unknown
Lisbon, Portugal

Peter Hoskin MD
Consultant Clinical Oncologist
Mount Vernon Cancer Centre
Northwood, UK

Patrick McLaughlin MD
Professor of Radiation Oncology
University of Michigan
Ann Arbor, MI

Jeff Michalski MD MBA
Professor of Radiation Oncology
Vice Chairman of Radiation Oncology
Chief of Genitourinary Service
Washington University in St. Louis
St. Louis, MO

Allan Pollack MD PhD
Chairman of Radiation Oncology
Professor of Radiation Oncology
University of Miami
Miami, FL

Mack Roach MD
Professor of Radiation Oncology and Urology
Director of Particle Therapy Research
Program & Outreach
Department of Radiation Oncology
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Howard Sandler MD MS
Chair in Cancer Therapeutics
Professor and Chair,
Department of Radiation Oncology
Cedars-Sinai Medical Center
Los Angeles, CA

Matthew Smith MD PhD
Professor of Medicine
Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital
Cancer Center
Boston, MA

Daniel Eidelberg Spratt MD
Assistant Professor
Chief of the Genitourinary Program
Department of Radiation Oncology
University of Michigan
Ann Arbor, MI

Robert Timmerman MD
Professor of Radiation Oncology
Neurological Surgery
UT Southwestern Medical Center
Dallas, TX

Anthony Laurence Zietman MD
Professor of Radiation Oncology
Director of GU Service
Massachusetts General Hospital
Boston, MA

MSK CO-COURSE DIRECTORS

Marisa A. Kollmeier MD
Radiation Oncologist, Attending

Sean McBride MD MPH
Radiation Oncologist, Attending

MSK COURSE DIRECTOR

Michael J. Zelefsky MD
Vice Chair, Department of Radiation Oncology,
Clinical Research; Chief, Brachytherapy Service

Marisa A. Kollmeier MD
Radiation Oncologist, Attending

Michael J. Zelefsky MD
Vice Chair, Department of Radiation Oncology,
Clinical Research; Chief, Brachytherapy Service
Thursday, December 8, 2016

7:00-7:50 am  BREAKFAST & REGISTRATION
7:50-8:00 am  Welcome & Introduction  Michael J. Zelefsky MD

SESSION A:  Comparative Outcomes and Toxicity Management
8:00-9:15 am  Comparison of Outcomes and Toxicities and QOL between Treatment Interventions  MODERATOR: Marisa A. Kollmeier MD
  • Comparison of Surgery and Radiotherapy for High Risk Disease: The Urologist’s Perspective  James Eastham MD
  • Comparison of Surgery, EBRT and Brachytherapy Based Modalities for High Risk Disease - The Radiation Oncologist Perspective  Mack Roach MD
  • Comparison of Toxicity and QOL Outcomes between Surgery and Radiotherapeutic Interventions  Jeff Michalski MD, MBA
  • Panel Discussion - Q&A

9:15-10:30 am  Optimal Use of Androgen Deprivation Therapy (ADT) and Radiotherapy  MODERATOR: Sean McBride MD MPH
  • Optimal Duration of ADT for Intermediate and High Risk Disease  Anthony Victor D’Amico MD PhD
  • Managing the Side Effects of Prolonged ADT?  Susan Slovin MD PhD
  • Maintaining Bone Health for the Patient Treated with ADT  Matthew Smith MD PhD
  • Panel Discussion and Q&A

10:30-11:00 am  COFFEE BREAK
11:00-12:00 pm  Optimizing Management of Side Effects after EBRT and Brachytherapy  MODERATOR: Michael J. Zelefsky MD
  • Addressing GI Toxicity  Marisa A. Kollmeier MD
  • Addressing GU Toxicity  Jaspreet S. Sandhu MD
  • Addressing Sexual Dysfunction  John Mulhall MD
  • Panel Discussion and Q&A

12:00-1:00 pm  Imaging for Prostate Cancer- Impact on Staging and Treatment Selection  MODERATOR: Sean McBride MD MPH
  • MP-MRI: Opportunities to Assess and Predict Treatment Response  Evis Sala MD PhD
  • Molecular Imaging and Novel Tracers in Prostate Cancer  Heiko Schoder MD
  • Putting It All Together: Using Imaging From Diagnosis to Treatment Assessment  Steven Jay Frank MD
  • Panel Discussion and Q&A

1:00-2:00 pm  LUNCH BREAK

SESSION B:  Radiotherapy Treatment Interventions: Technical Aspects
2:00-3:15 pm  Brachytherapy: Indications, Tumor Control Outcomes and Toxicity and Advances in the OR  MODERATOR: Marisa Kollmeier MD
  • LDR-Indications, Relative Contraindications, and Where Are We in 2016  Juanita Crook MD
  • HDR Indications, Relative Contraindications, and Where Are We in 2016  Peter Hoskin MD
  • Advances in the Operating Room: Real Time Treatment Assessments and Imaged Based Fusions for Dose Intensification  Michael J. Zelefsky MD
  • Optimal QA in the OR- Reducing Errors  Gilad Cohen MS
  • Panel Discussion and Q&A
3:15-4:15 pm  **Structure Contouring: Basic Anatomy and What's New?**
MODERATOR Richard M. Gewanter MD

- MRI Anatomy of the Prostate and Critical Normal Tissues
  Patrick McLaughlin MD
- Contouring the Pelvic Nodes with Confidence
  Daniel Eidelberg Spratt MD
- Multi-modality Image Registration and Fusion: Evaluating uncertainty and building confidence
  Kristy Brock-Leatherman PhD
- Panel Discussion and Q&A

4:15-4:30 pm  **COFFEE BREAK**

4:30-6:00 pm  **Advances in External Beam Treatment Planning and Delivery**
MODERATOR Neelam Tyagi PhD

- Guidelines for Target and Normal Tissue Dose Constraints for EBRT and SBRT
  Laura Happersett MS
- Refining the State-of-the-Art: Simulation through Treatment Planning: What are the New Treatment Planning Programs Able to Accomplish?
  James G. Mechalakos PhD
- Advances in Multi-Modality Image-Based Planning and MR-Based Simulation
  Carri Glide-Hurst PhD
- Treatment Delivery: Novel Approaches to Address Motion Reduction and Image Guidance
  Margie A. Hunt MS
- Panel Discussion and Q&A

6:00-6:45 pm  Cocktail Reception & Poster Presentations

**Friday, December 9, 2016**

7:30-8:00 am  BREAKFAST

**SESSION C:**
Novel Radiotherapy Treatment Interventions: Clinical Aspects

8:00-9:00 am  **Department of Medicine Grand Rounds**
Biomarkers and Genomics for Prostate Cancer
Philip Kantoff MD

9:15 10:30 am  **SBRT Outcomes and Advances**
MODERATOR Peter Hoskin MD

- Tumor Control Outcomes and Toxicity for SBRT
  Michael J. Zelefsky MD
- Moderate Hypofractionation
  Allan Pollack MD PhD
- High Dose Fractionated SBRT
  Robert Timmerman MD
- Single Dose Radiotherapy for Localized Disease
  Carlo Greco MD
- Panel Discussion and Q&A

10:30-10:45 am  **COFFEE BREAK**

TO REGISTER TODAY, PLEASE VISIT:
www.mskcc.org/Radiotherapy
10:45-11:45 am Proton Therapy: Is there an Established Role in the Treatment of Localized Disease?
MODERATOR: Oren Cahlon MD
• Clinical Outcomes & Toxicity and Tolerance Profiles and Comparison to Photon IMRT
  Anthony Laurence Zietman MD
• Treatment Planning Challenges
  Stefan Both PhD
• Cost Effectiveness of Protons versus Other Radiotherapeutic Interventions- Is there a Winner?
  Steven Jay Frank MD
• Panel Discussion and Q&A

11:45-1:00 pm Improving Our Radiotherapy Outcomes for Intermediate and High Risk Prostate Cancer
MODERATOR: Anthony Laurence Zietman MD
• Important Considerations for Optimizing Outcomes for Local & Regional Therapy Using Radiotherapy in Intermediate and High Risk Disease
  Marisa A. Kollmeier MD
• Elective Lymph Node Irradiation for Prostate Cancer: When, How and Is it Worth it?
  Mack Roach MD
• Ongoing and Protocols in the Works for Prostate Cancer
  Howard Sandler MD MS
• Strategies Incorporating Targeted Therapy and Novel Anti-androgen and Radiotherapy
  Sean McBride MD MPH
• Panel Discussion and Q&A

1:00-1:45 pm LUNCH BREAK

SESSION D: Salvage Therapy after Primary Treatment Failure

1:45-2:45 pm Salvage Radiotherapy after Surgery
MODERATOR: Howard Sandler MD MS
• Salvage versus Adjuvant Radiotherapy following Radical Prostatectomy
  Anthony Victor Damico MD PhD
• Optimal Contouring and Treatment planning considerations in the Salvage Setting
  Allan Pollack MD PhD
• The Role of Hormonal Therapy in the Salvage Setting
  Anthony Laurence Zietman MD
• Panel Discussion and Q&A

2:45-3:45 pm Salvage Options after RT failure
MODERATOR: Michael J. Zelefsky MD
• Outcomes with Brachytherapy as Salvage for Radio-Recurrent Disease
  Marisa A. Kollmeier MD
• Outcomes of Surgery and Other Approaches in the Salvage Setting
  Jonathan Coleman MD
• Focal Therapy Options and Outcomes
  Mark Emberton MD
• Panel Discussion and Q&A

3:45 pm ADJOURN
Registration includes continental breakfast, lunch, and refreshment breaks. Please contact us at least one week prior to the course if you have any special dietary needs.

Registration is complimentary for MSK staff who wish to attend this course. However, you must register online by visiting the course website, www.mskcc.org/radiotherapy.

<table>
<thead>
<tr>
<th>Registration Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDs, PhDs, DOs, and Medical Physicists</td>
<td>$500</td>
</tr>
<tr>
<td>MSK Alliance and MSK Alumni</td>
<td>$350</td>
</tr>
<tr>
<td>Residents, Fellows, RNs, Medical Students and other Healthcare Providers</td>
<td>$250</td>
</tr>
<tr>
<td>Industry Members*</td>
<td>$875</td>
</tr>
</tbody>
</table>

*Industry Members: Registration is for educational purposes only. Marketing, sales, and promotion of products and services are prohibited at CME activities.

To register today, please visit: www.mskcc.org/Radiotherapy

Registration includes continental breakfast, lunch, and refreshment breaks. Please contact us at least one week prior to the course if you have any special dietary needs.

Registration is complimentary for MSK staff who wish to attend this course. However, you must register online by visiting the course website, www.mskcc.org/radiotherapy.

To register today, please visit: www.mskcc.org/Radiotherapy

COURSE DESIGN
This course includes hands-on review of cases which will be intermixed with short didactic lectures.

EVALUATION
A course evaluation survey sent out electronically will provide attendees with the opportunity to review the sessions and the speakers and to identify future educational needs.

OUTCOMES MEASUREMENT SURVEY
Six months after the end of the course, an Outcomes Measurement Survey will be sent to all participants to help us determine what positive impacts have been made on participant practice as a result of the course.

ACCREDITATION STATEMENT
MSK is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT
MSK designates this live activity for a maximum of 15.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. The AMA has determined that physicians not licensed in the United States but who participate in this CME activity are eligible for 15.5 AMA PRA Category 1 Credit(s)™.

FACULTY DISCLOSURE
It is the policy of MSK to make every effort to ensure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it sponsors as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity sponsored by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

ACCOMMODATIONS
For information on hotels in the area of MSKCC with discounted rates, please visit: www.mskcc.org/accommodations.